Iroko Pharmaceuticals Selects Aptuit, Inc. as Contract Manufacturing Partner for Phase III Lower-Dose NSAID Programs Formulated Using the SoluMatrix(TM) Nanotechnology Platform

PHILADELPHIA & GREENWICH, Conn.--(BUSINESS WIRE)--Iroko Pharmaceuticals, LLC and Aptuit Inc. announced today that Aptuit will provide manufacturing scale-up services as Iroko progresses its novel pain medications to Phase III clinical trials.